Becton Dickinson (NYSE:BDX) sells healthcare necessities, including needles, syringes and other basic supplies that medical professionals use to collect and analyze their specimens. Sales and profits aren't expanding as briskly as in recent years, but there are still plenty of reasons to consider investing in the stock.
Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

First Quarter Recap
Revenues advanced a modest 2.5% to $1.9 billion. Excluding foreign currency translations, Becton stated that, on this "foreign currency-neutral" basis, sales rose 2.4%, meaning foreign exchange impacts were minimal during the quarter. U.S. revenue was flat at $828.8 million, or roughly 44% of total sales. The rest stemmed from international revenues, which rose a much stronger but still modest 4.5%.

By division, the medical segment, which sells Becton's flagship needles, syringes and related consumable medical products, grew 2.6% to account for just over half of the total top line. The diagnostic unit sells systems to help medical clinics, labs such as Quest Diagnostics (NYSE:DGX) and Laboratory Corporation (NYSE:LH), and hospitals such as Health Management Associates (NYSE:HMA) and HCA Holdings (NYSE:HCA) collect and transport medical specimens. It reported a 3.2% sales rise to account for nearly a third of total sales. The bioscience unit eked out 0.9% growth to account for the remaining 17% of sales. It provides research and clinical tools to help its clients analyze and develop drugs, such as during the clinical trial process.

Reported operating income fell 13.2% to $358.6 million, while net income fell a slightly more severe 16.8% to $263 million. Share buybacks tempered the earnings per diluted share decline to 11% as the bottom line fell to $1.21. Management attributed the negative sales leverage to "difficult pricing comparisons, higher raw material costs and higher expenses from recent acquisitions." (To know more about income statements, read Understanding The Income Statement.)

Outlook
Though currency fluctuations didn't have much impact on the first quarter, Becton expects it to reduce earnings from its previous guidance of $5.75 to $5.85 per diluted share. It now projects a range of $5.60 to $5.70, or within the range of the $5.62 per diluted share it reported last year. It still expects sales growth of 2 to 4% from the $7.8 billion reported last year.

The Bottom Line
Becton Dickinson isn't growing very rapidly lately, but still has a stellar long-term track record. Over the past decade, sales are up close to 8% annually while earnings are up more than 14%. During this timeframe, management has steadily boosted profitability, with operating earnings rising from less than 17% to right around 22%. Returns on equity are up above 25% while return on invested capital is consistently in the mid to high teens.

At a forward P/E of 12.3, the valuation is reasonable. Becton's sales are relatively stable given it sells basic necessities in the healthcare industry, which itself is relatively recession resistant. The majority of sales also stem from overseas, which should see above-average growth going forward. Profitability is high, the dividend yield is decent at 2.3%, and there is upside potential should profit growth start trending back up closer to historical levels. (For additional reading, check out 5 Must-Have Metrics For Value Investors.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  2. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  7. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  8. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  9. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  10. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center